LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up

Ma, Martínez-Castellanos; Schwartz, Shulamit; Ml, Hernández-Rojas; Va, Kon-Jara; García-Aguirre, Gerardo; Jl, Guerrero-Naranjo; Rv, Chan; Quiroz‐Mercado, Hugo

doi:10.1097/iae.0b013e318275394a

Cited by 112 publications

(77 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The reported mean SE was between À 1.04 to 0.64 D between 1 and 2 years old, which was similar to that of our patients who were treated with IVB only ( À 0.98 D). 9,10,17 Our study and other case series found a lower SE in patients treated with IVB than in patients treated with cryotherapy (range, À 6.5 to À 3.51 D) or with laser peripheral ablative therapy (range, À 4.71 to À 1.50 D). [3][4][5][6][7] Our prevalences of myopia and high myopia are also similar to those of preschool-age patients in a recent case series who were treated with IVB only (55.6% and 11.1 to 17.0%) ( Table 3).…”

Section: Eyementioning

confidence: 72%

“…[3][4][5][6][7] Our prevalences of myopia and high myopia are also similar to those of preschool-age patients in a recent case series who were treated with IVB only (55.6% and 11.1 to 17.0%) ( Table 3). 9,10,17 In the current study, the prevalences of myopia and high myopia increased significantly with the severity of ROP but were not associated with AXL changes. It is commonly understood that eyes treated with cryotherapy and peripheral laser photocoagulation are more myopic.…”

Section: Eyementioning

confidence: 82%

“…9,10,12,17 Many authors have stated that myopia occurs frequently in infants who develop ROP and increases with the severity of the ROP. 5,6 The refractive error abnormalities of ROP patients have been found to present early in infancy and persist into adulthood.…”

Section: Discussionmentioning

confidence: 99%

“…Currently, there are only three case series and one case report that discuss the refractive changes after the use of IVB. 9,10,12,17 To the best of our knowledge, this is the largest study cohort to examine refraction composition in infants who received IVB-based treatment. Previous Fisher's exact test.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Chen

et al. 2014

Eye

View full text Add to dashboard Cite

Section: Eyementioning

confidence: 72%

Section: Eyementioning

confidence: 82%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Chen

et al. 2014

Eye

View full text Add to dashboard Cite

“…The role of vascular endothelial growth factor (VEGF) in the pathogenesis and progression of ROP has been well documented (1,2). The beneficial effects of intravitreal anti-VEGF agents in ROP management have been shown in previous studies (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). In a randomized and controlled multicenter study of stage 3 ROP with plus disease, intravitreal bevacizumab therapy appeared to excel conventional laser therapy for Zone I disease, and had comparable results with laser therapy for Zone II disease (8).…”

Section: Introductionmentioning

confidence: 99%

Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

et al. 2016

View full text Add to dashboard Cite

Background/aim: To evaluate refractive and strabismic results and the efficacy of intravitreal bevacizumab in retinopathy of prematurity (ROP) ineligible for laser therapy. Materials and methods:Thirty-nine eyes of 20 consecutive infants with high-risk prethreshold ROP (11 infants with Zone I and 9 infants with Zone II disease) who were ineligible for laser therapy due to systemic and/or ocular conditions were treated with intravitreal bevacizumab. Recurrent retinopathy was treated with laser ablation. The final follow-up examination was performed at 29.8 ± 6.0 months of corrected age.Results: All eyes responded to the initial treatment with intravitreal bevacizumab. ROP recurred in 8 eyes (36%) with initial Zone I disease and in only 2 eyes (11%) with initial Zone II disease, which were successfully treated with laser ablation. No eye developed myopia higher than 5.0 diopters. At 2.5 years, the Zone I eyes that had received laser treatment appeared to be more myopic than the Zone I eyes treated only with intravitreal bevacizumab (P = 0.038). A tendency for a higher incidence of strabismus after additional laser therapy was also noted, but was not significant (P = 0.22). Conclusion:Avoidance or even deferral of laser ablation with intravitreal bevacizumab may lead to less myopization in ROP compared with conventional laser treatment.

show abstract

Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity

Stahl,

Nakanishi,

Lepore

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceProspective long-term data after retinopathy of prematurity (ROP) treatment with anti–vascular endothelial growth factor injections vs laser therapy are scarce. The FIREFLEYE (Aflibercept for ROP IVT Injection vs Laser Therapy) next trial is prospectively evaluating the long-term efficacy and safety outcomes following ROP treatment with intravitreal aflibercept vs laser therapy.ObjectiveTo evaluate 2-year ophthalmic and safety outcomes after 0.4-mg aflibercept injection or laser therapy in the 24-week randomized (2:1) FIREFLEYE trial (FIREFLEYE outcomes previously reported).Design, Setting, and ParticipantsThis prospective nonrandomized controlled trial performed in 24 countries in Asia, Europe, and South America (2020-2025) follows up participants treated in the FIREFLEYE randomized clinical trial (2019-2021) through 5 years of age. Participants included children born very or extremely preterm (gestational age ≤32 weeks) or with very or extremely low birth weight (≤1500 g) who were previously treated with a 0.4-mg injection of aflibercept compared with laser therapy for severe acute-phase ROP. Data for the present interim analysis were acquired from March 18, 2020, to July 25, 2022.InterventionsComplications of ROP treated at investigator discretion (no study treatment).Main Outcomes and MeasuresEfficacy end points included ROP status, unfavorable structural outcomes, ROP recurrence, treatment for ROP complications, completion of vascularization, and visual function. Safety end points included adverse events and growth and neurodevelopmental outcomes.ResultsOverall, 100 children were enrolled (median gestational age, 26 [range, 23-31] weeks; 53 boys and 47 girls). Of these, 21 were Asian, 2 were Black, 75 were White, and 2 were of more than 1 race. At 2 years of age, 61 of 63 children (96.8%) in the aflibercept group vs 30 of 32 (93.8%) in the laser group had no ROP. Through 2 years of age, 62 of 66 (93.9%) in the aflibercept group and 32 of 34 (94.1%) in the laser group had no unfavorable structural outcomes. No new retinal detachment occurred during the study. Four children in the aflibercept group (6.1%) were treated for ROP complications before 1 year of age (2 had preexisting end-stage disease and total retinal detachment; 1 had reactivated plus disease; and 1 had recurrent retinal neovascularization not further specified). Most children were able to fix and follow a 5-cm toy (aflibercept group, 118 of 122 eyes [96.7%] among 63 children; laser group, 62 of 63 eyes [98.4%] among 33 children). High myopia was present in 9 of 115 eyes (7.8%) among 5 children in the aflibercept group and 13 of 60 eyes (21.7%) among 9 children in the laser group. No relevant differences in growth and neurodevelopmental outcomes by Bayley Scales of Infant and Toddler Development, Third Edition and Vineland Adaptive Behavior Scales, Second Edition were identified.Conclusions and RelevanceIn this nonrandomized follow-up of a randomized clinical trial comparing treatment of severe acute-phase ROP with 0.4-mg injection of aflibercept and laser, disease control was stable and visual function was appropriate in children through 2 years of age. No adverse effects on safety, including growth and neurodevelopment, were identified. These findings provide clinically relevant long-term information on intravitreal aflibercept injection therapy for ROP.Trial RegistrationClinicalTrials.gov Identifier: NCT04015180

show abstract

LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up

Abstract: Five years of follow-up in a small series suggest that intravitreal bevacizumab for retinopathy of prematurity results in apparently preserved ocular function and systemic development.

Cited by 112 publications

References 45 publications

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Intravitreal bevacizumab for retinopathy of prematurity in infants ineligible for laser therapy*

Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity

Contact Info

Product

Resources

About